The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential

Mohamed H. Al-Sabri1, Maryam Nikpour1,3, Laura E. Clemensson1, Misty M. Attwood1, Michael J. Williams1, Mathias Rask-Anderson2, Jessica Mwinyi1 and Helgi B. Schiöth1*

Abstract
Monoaminergic neurotransmitter systems play a central role in neuronal function and behaviour. Dysregulation of these systems gives rise to neuropsychiatric and neurodegenerative disorders with high prevalence and societal burden, collectively termed monoamine neurotransmitter disorders (MNDs). Despite extensive research, the transcriptional regulation of monoaminergic neurotransmitter systems is not fully explored. Interestingly, certain drugs that act on these systems have been shown to modulate central levels of the transcription factor AP-2 beta (AP-2β, gene: TFAP2β). AP-2β regulates multiple key genes within these systems and thereby its levels correlate with monoamine neurotransmitters measures; yet, its signalling pathways are not well understood. Moreover, although dysregulation of TFAP2B has been associated with MNDs, the underlying mechanisms for these associations remain elusive. In this context, this review addresses AP-2β, considering its basic structural aspects, regulation and signalling pathways in the controlling of monoaminergic neurotransmitter systems, and possible mechanisms underpinning associated MNDs. It also underscores the significance of AP-2β as a potential diagnostic biomarker and its potential and limitations as a therapeutic target for specific MNDs as well as possible pharmaceutical interventions for targeting it. In essence, this review emphasizes the role of AP-2β as a key regulator of the monoaminergic neurotransmitter systems and its importance for understanding the pathogenesis and improving the management of MNDs.

Keywords: Transcription factor AP-2 beta, AP-2β, TFAP2B, Monoaminergic neurotransmitter systems, Dopamine, Noradrenaline, Serotonin, Monoamine neurotransmitter disorders, Polymorphisms, Obesity, Neuroblastoma, Diagnostic biomarker and therapeutic target

Background
The monoaminergic neurotransmitter systems, including dopaminergic (DA), adrenergic, noradrenergic (NA) and serotonergic (5-HT) circuitries, regulate a wide range of neurological functions. Dysregulation of these systems is associated with a variety of neuropsychiatric, neurodevelopmental and neurodegenerative disorders, which forms the basis for the so-called monoamine neurotransmitter disorders (MNDs) [1, 2], including obesity, type 2 diabetes (T2D), anxiety, depression, alcoholism, Alzheimer’s disease (AD), and neuroblastoma, several of which are among the leading causes of death and disability worldwide [3].
The intricate interplay between monoamine neurotransmitters in the pathophysiology of MNDs poses a substantial challenge for treatment strategies. For instance, dopamine and serotonin, together with norepinephrine, regulate neurological functions ranging from eating behaviour and memory to psychiatric disorders, including aggression, anxiety and depression [4–10]. On the other hand, current treatment options targeting different proteins in monoaminergic systems are far from optimal. In particular, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and catechol-O-methyltransferase inhibitors (COMTIs) are associated with serious adverse and off-target effects as well as interactions with foods and other drugs, resulting in poor patient compliance and treatment outcomes [11–18].

The transcription factor activating protein 2 beta (AP-2β, gene: TFAP2B) AP-2β has emerged as a vital transcription factor, regulating multiple key genes in monoaminergic neurotransmitter systems such as the serotonin transporter (5-HTT) [19, 20], COMT [21], dopamine-beta-hydroxylase (DBH) [22], vesicular monoamine transporter 2 (VMAT2) [23] and others. Subsequently, AP-2β levels correlate positively with monoamine neurotransmitter indices in the brain [24, 25]. In terms of MNDs, not only is TFAP2B associated with reduced anxiety [26, 27], alcoholism [28], obesity [29], binge-eating disorder (BED) [30] and T2D [31], but it also plays a neuroprotective role in AD [32] and neuroblastoma [33]. Together with its role in MNDs, the ability of AP-2β to selectively regulate key genes in the monoamine neurotransmitter pathways underlines its potential in the early diagnosis and management of associated MNDs [33–37]. This is supported by the fact that certain drugs acting on monoaminergic neurotransmitter systems, phenelzine (MAOI) and citalopram (SNRI), have been shown to modulate the brainstem levels of AP-2β [38, 39]. Therefore, in order to improve current treatment options for MNDs, a better understanding of AP-2β role in the regulation of monoaminergic neurotransmitter systems is essentially required.

Despite extensive studies on AP-2β crucial role in monoaminergic neurotransmitter systems, little is known about its signalling pathways in controlling these systems, making the underlying mechanisms for associated MNDs rather ambiguous. Thus, we review studies on the AP-2β basic structure, its overarching signalling pathways in the control of monoaminergic neurotransmitters and its polymorphisms associated with MNDs. Also, we discuss possible underlying mechanisms for these associations. Most importantly, we explore its usefulness as a diagnostic biomarker for specific MNDs and underline key opportunities and challenges for targeting it.

The AP-2 transcription factor family, structure and transduction mechanisms

The transcription factor activating protein 2 (AP-2) was first cloned in 1987 [40]. At present, five members of the transcription factor AP-2 have been identified: AP-2α, AP-2β, AP-2γ, AP-2ζ and AP-2η, which are encoded by TFAP2A/α, TFAP2B/β, TFAP2C/γ, TFAP2D/δ, TFAP2E/ε respectively [41]. The AP-2 proteins are highly conserved across species [42] and have differential expression and functions, thereby their mutations give rise to diverse disorders, see Table 1. Structurally, they can form either hetero- or homodimers with a molecular weight of around 50 kDa. They share three regions: a highly conserved C-terminal helix–span–helix homodimerization motif, which starts with a glutamine amino acid; followed by a central basic region, both regions constitute the DNA binding domain; and a less conserved N-terminal proline- and glutamine-rich transactivation region responsible for protein binding domain [42–45] (Fig. 1).

There are two DNA binding sites for AP-2: 2 cis-acting DNA sequences 5’-(G/C)CCCA(G/C)(G/C)(G/C)-3’ and the palindromic sequence 5’-GCCNNNGGC-3’ [27, 46, 47]. Except for AP-2ζ, the transactivation domain of AP-2 proteins is characterized by a PY motif (XPPXY) and other highly conserved residues in the protein binding domain [48]. Despite structure similarities (76% homology) between AP-2α & AP-2β [49], their gene mutations give rise to different phenotypes (Table 1). Moreover, AP-2α-null mice exhibit severe craniofacial defects while AP-2β KO mice display massive apoptosis of renal cells and terminal renal failure [49–52]. This might indicate that they are involved in differential signalling pathways. Although the crystal structure of each AP-2 protein has not yet been established, a highly accurate prediction of their protein structures has been produced by AlphaFold [53] and is available at Uniprot (Q92481).

AP-2 transcription factors are prominent regulators of multiple genes involved in embryonic neural crest development, cell differentiation and haemostasis in a range of tissues but mainly in central and peripheral nervous and urogenital systems [42, 43, 55]. They mediate induction of the target genes in response to two signal-transduction mechanisms: phorbol-ester- and diacylglycerol-activated protein kinase C (PKC) and cAMP-dependent protein kinase A (PKA) [30, 51, 56, 57]. AP-2 transcription factors can act both as transcriptional activators or repressors of the target genes; therefore, we suggest that the name ‘transcription factor activating protein 2 (AP-2)’ used in the literature is actually a misnomer and should
| AP-2 Name | Expression | Function | Linked diseases and disorders |
|-----------|------------|----------|------------------------------|
| AP-2α / TFAP2A | Neural crest cells & tube of CNS PNS including facial and limb mesenchyme, extraembryonic trophoderm, human villous cytotrophoblast cells, breast, skin, kidney, retina, adipose tissue, and bone: cartilage and others [42, 61, 242–246] | Regulation of monoamine turnover [62] Specification of GABAergic and glycnergic interneurons [63] Regulate melanocyte [247] and nephron differentiation [248] Play a key role in trophoderm development [249] A suppressor of chondrocyte differentiation during cartilage development [243, 245, 246] | Mutation causes Branchio-oculo-facial syndrome (BOFS) and ectopic thymus; anophthalmia-microphthalmia syndrome [115, 250] As an activator of gallbladder carcinoma [251] As a suppressor of hepatocellular carcinoma, breast cancer, glioblastoma, melanoma, gastric, prostate, and colorectal cancers [115, 252–257] As an oncogene in acute myeloid leukaemia, squamous cell, nasopharyngeal and pancreatic cancers and neuroblastoma [115, 258–262] |
| AP-2β / TFAP2B | Fatal neural crest cells, sympathetic neuroblasts of CNS and PNS including facial and limb mesenchyme Heart, smooth and skeletal muscles, collecting duct and distal tubules, kidney, parts of the reproductive system such as prostate and endometrium, retina, adipose tissue; respiratory and endocrine systems including thyroid, adrenal medulla, mammary, sweat, salivary glands and skin [34, 42, 46, 58, 61, 80, 82, 214, 216, 242] | Enhance monoaminergic neurotransmitter activity including serotoninergic, dopaminergic and adrenergic transmission through controlling the key genes in monoaminergic neurotransmitter systems [24, 30, 46, 62, 82, 149] Crucial for intrauterine growth, differentiation of distal nephrons and the sympathetic ganglia and neurons, maturation of chromaffin cells of the adrenal medulla and specification of GABAergic and glycnergic interneurons [46, 46, 63, 80] Regulation of adipocytokines, insulin signalling and fat metabolism [29, 34, 134, 135, 263] Proliferation and differentiation of extraembryonic trophodermal cells [244, 264] | Mutation causes Char syndrome and Patent ductus arteriosus 2, dental anomalies, and terminal renal failure [64–67, 265] Unfavourable prognostic factor in neuroblastoma [33], lung adenocarcinoma [216], breast [221–223] & thyroid cancers [215] Favourable prognostic factor in endometrial carcinoma [217], cervical cancer [224, 225], & renal cell cancer [218–220] Its dysregulation is associated with obesity and adiposity-related disorders including, binge-eating disorders, anorexia and bulimia nervosa and diabetic Mellitus [26, 29, 30, 35, 36, 79, 61, 125] |
| AP-2γ / TFAP2C | Kidney, neural crest cells, and human villous cytotrophoblast cells [42, 244] | As a negative regulator of the other AP-2 family members [42] Play a key role in trophoderm development [244, 264] Regulates key genes responsible for eyes, face, and limb formation or neural tube development [115] Control the expression of other genes such as FOXA1, WWOX, GREB1, CDH2, HPSE, IGSS1 and others [263] | Mutation causes Exencephaly, melanoma and pre-eclampsia [115] Act as an oncogenic factor in many cancers such as melanoma, neuroblastoma, breast, testicular and lung cancers [115, 266–269] |
| AP-2δ / TFAP2D | Brain, placenta, skeletal muscle, thymus, small intestine, retina, heart, and prostate [270, 271] | Important during embryogenesis and in retina development [271, 272] Regulation of the HMOX1 gene[273] | Associated with aggressive prostate cancer [274] |
| AP-2ε / TFAP2E | Neural tissue of the midbrain and hindbrain [275], cells and vomeronasal sensory neurons of the olfactory bulb [276, 277], and cartilage [278] | Important for development of GABAergic interneurons in olfactory bulb [276, 277, 279] Regulation of integrin α10 transcription and the core promoter of type II collagen (COL2A1) Crucial for chondrogenesis and the development of cartilage during embryogenesis [278, 280, 281] | Associated with colorectal cancer [282] and neuroblastoma [263, 283] Implicated in hypertrophic cartilage and the development of osteoarthritis [278] |

**FOX1** Forkhead Box A1, **WWOX** WW Domain Containing Oxidoreductase, **GREB1** Growth Regulating Estrogen Receptor Binding 1, **CDH2** Cadherin-2, **HPSE** Heparanase, **IGSF11** Immunoglobulin Superfamily Member 11, **HMOX1** Heme Oxygenase 1, **COL2A1** Core promoter of type II collagen
be considered as ‘transcription factor trans-regulator protein 2 (TP-2)’.

**AP-2β transcription factor**

AP-2β was first characterized in 1995 [41]. Two splice variants for AP-2β have been identified, both can exert transcriptional regulatory activity but have a different in tissue expression: one short at 198 aa (22.1 kDa) (UniProt ID X6R4Y8), which is not well studied, and one long at 460 aa (50.5 kDa) (UniProt Q92481) that has been thoroughly investigated [58, 59]. AP-2β is highly expressed in the brain and peripheral neurons, eyes, smooth muscles of ductus arteriosus, skin, bone marrow, adipose and lymphoid tissues, proximal digestive tract, the adrenal medulla of the kidney and across the urogenital system [36, 58, 60]. In addition to its function in monoaminergic neurons, TFAP2B is also involved in specification of glycinergic and GABAergic interneurons [61–63]. TFAP2B mutations lead to the development of severe disorders such as craniosynostosis, Char Syndrome, dental anomalies, defects in patent ductus arteriosus, terminal renal failure and others [64–67] (Table 1).

**Regulation of AP-2β activity**

To better understand its associated MDNs, the mechanisms regulating AP-2β activity should be first articulated. Two key mechanisms have been shown to modulate the DNA-binding and/or transcriptional activities of AP-2β: protein–protein interactions through the protein-binding domain and post-translational modifications employing the DNA-binding domain (Figs. 1 and 2).

**Protein–protein interactions**

AP-2β has a specific protein-binding domain, also known as a transactivation domain [44, 45, 67]. Binding to this domain modulates the DNA-binding ability of AP-2β at the adjacent DNA-binding domain [67]. A study by Ding et al. has shown, for example, that the potassium channel tetramerization domain 1 (KCTD1) binds to the N-terminal protein-binding domain of AP-2β and inhibits its transcriptional activity in human...
cell lines [68]. Another study by Zarelli et al. has reported that in zebrafish, potassium channel tetramerization domain 15 (KCTD15) inhibits the expression of AP-2 [69]. Interestingly, KCTD1 and KCTD15 have remarkably similar amino acid sequences [70], which may explain the similarity of their effects on AP-2β. Additional inhibitors of AP-2β transcriptional activity are the protein kinase D (PKD) [71], which, by phosphorylating AP-2β, inhibits its DNA binding activity, as well as the hypoxia-inducible factor-2alpha (HIF-2α), which negatively regulates the expression AP-2β [72].

The dynamics of protein–protein interaction can also lead to enhanced AP-2β activities. Cpb/p300-interacting transactivator 2 & 4 (CITED2 & CITED4), are coactivators and enhancers of AP-2β-induced transcriptional activation [73, 74]. Additionally, YEATS domain-containing protein 4 (YEATS4, also known as GAS41) augments both, the DNA-binding and the transactivation domain-containing protein 4 (YEATS4, also known as CITED4) [73, 74]. Yeast activator of transcription 4 (YEATS4), with remarkably similar amino acid sequences [70], which may explain the similarity of their effects on AP-2β.

The coactivators and suppressors of AP-2β

Post-translational modifications

Post-translational modification is another mechanism that can modulate the transcriptional or DNA-binding activity of AP-2β. For example, the sumoylation of AP-2β by ubiquitin carrier protein 9 (UBC9) has been shown to decrease its transcriptional activity [77]. KCTD15 mentioned earlier can also enhance the activity of AP-2β through sumoylation [78, 79]. Accordingly, KCTD15 can modulate the activity of AP-2β directly (blocking) and post-translationally (activating) (Table 2).

In summary, different modulators have been shown to regulate the activity of the AP-2β by two mechanisms: the protein–protein interaction through the transactivation domain and post-transcriptional modification through the DNA-binding domain. These two mechanisms could be utilized to pharmacologically modulate AP-2β activity, possibly by targeting these modulators.

**Table 2** The coactivators and suppressors of AP-2β

| Suppressor  | Coactivators/positive regulators |
|------------|----------------------------------|
| KCTD1 [68] | KCTD15 sumoylation [78, 79]      |
| KCTD15 [69]| CITED2 [73]                      |
| UBC9 sumoylation [77] | CITED4 [74] |
| PKD phosphorylation [71] | YEATS4 [75] |
| HIF-2α [72] |                                   |

KCTD1: the potassium channel tetramerization domain 1; KCTD15: potassium channel tetramerization domain 15; PKD: protein kinase D; HIF-2α: inducible factor-2alpha; CITED2: Cpb/p300-interacting transactivator 2; CITED4: Cpb/p300-interacting transactivator 4; YEATS4: YEATS domain-containing protein 4; UBC: ubiquitin carrier protein 9; UBE2I: ubiquitin-conjugating enzyme E2I

**AP-2β signalling regulation of monoaminergic neurotransmitter systems**

AP-2β is a vital transcription factor for the proper development and function of the monoaminergic neurotransmitter systems [24, 62, 80]. It plays an essential role in the maturation of chromaffin cells, sympathetic neuronal differentiation, and regulation of monoaminergic transmission, including adrenergic, noradrenergic and dopaminergic, and serotonergic transmission, during both development and adulthood [24, 46, 62, 80–82]. Several key genes regulating the monoaminergic neurotransmitters’ biosynthesis, degradation and synaptic activity have a recognition site for AP-2β in their promoter regions [21–23, 27, 83, 84]. Since AP-2β enhances both monoaminergic transmissions, AP-2β levels correlate with monoamine neurotransmitter transmission in the brainstem [24, 25, 62]. This might explain why the central level of AP-2β has been changed after treatment with certain drugs that act on monoaminergic neurotransmitters, such as phenelzine (MAOI) and citalopram (SNRI) [24, 38, 85].

**AP-2β regulation of catecholaminergic transmission**

AP-2β plays a crucial role in the regulation of catecholamine levels in the brain by altering the expression of several key genes in the catecholaminergic pathway (Fig. 3). AP-2β enhances adrenergic transmission, boosting noradrenaline and epinephrine availability [24, 46, 86–88]. It activates the transcription of the genes of catecholamine-synthesizing enzymes, such as tyrosine hydroxylase (TH) [33, 82, 89], dopamine-beta-hydroxylase (DBH) [33, 46, 82, 89, 90] and phenylethanolamine N-methyltransferase (PNMT) [46, 86–88]. Furthermore, it lowers the genes of catecholamine-degrading enzymes, such as monoamine oxidase-A & B (MAO-A), (MAO-B) [28, 91–93] and COMT [21, 92].

Furthermore, AP-2β represses the Dopamine receptor D1A (DRD1A) receptor through binding to the D1A silencer 1 (D1AS1) [94]. Blocking this receptor leads to decreased adenylyl cyclase (AC) activity and lowered cyclic adenosine monophosphate (cAMP), resulting in dopamine-related behavioural changes such as reward, cognition and learning [94–96] (Fig. 3). DRD1A plays a significant role in the modulation of memory and cognition [97–99]; hence, it would be interesting to explore the association of TFAP2B polymorphisms with cognitive functions.

The effect of AP-2β on dopamine turnover is under debate. Damberg et al. have reported that AP-2β is
positively correlated with the indices of dopamine metabolites, namely homovanillic acid (HAV) and 3-methoxy-4-hydroxy-phenylglycol (MGPG) in rat forebrain [24] but not in CSF of humans [25]. Moreover, DBH enzyme is responsible for converting dopamine into norepinephrine in catecholaminergic neurons [100]; thus, given its transcriptional activation effect on DBH [33, 46, 82, 89, 90], AP-2β might enhance the turnover of dopamine by boosting its conversion into norepinephrine. On the other hand, Schabram et al. have suggested that AP-2β enhances dopamine availability and decreases its turnover through its repressing effect on MAO-A [28, 91–93] and COMT [21, 92]. AP-2β also represses the transcription of DRD1A through binding to its D1AS1 [94]. AP-2β: transcription activating protein 2 beta; TH: tyrosine hydroxylase; DBH: dopamine-beta-hydroxylase; PNMT: phenylethanolamine N-methyltransferase; MAO: monoamine oxidase; COMT: catechol-O-methyltransferase; HVA: homovanillic acid; VMA: 3-methoxy-4-hydroxymandelic acid; MHPG: 3-methoxy-4-hydroxy-phenylglycol; D1AS1: dopamine receptor 1A silencer 1; DRD1A: dopamine receptor 1A; AC: adenylyl cyclase; and cAMP: cyclic adenosine monophosphate.

**Fig. 3** The signalling pathway of AP-2β on catecholaminergic transmission where ‘−’ symbolizes repressing and ‘+’ activating effect of AP-2β on the transcription of its target genes. AP-2β stimulate the expression of key genes involved in catecholamine synthesis such as TH [33, 82, 89], DBH [33, 46, 82, 89, 90], PNMT [46, 86–88] while it lowers genes coding catecholamine degrading enzymes such as MAO [28, 91–93] and COMT [21, 92]. AP-2β also represses the transcription of DRD1A through binding to its D1AS1 [94]. AP-2β: transcription activating protein 2 beta; TH: tyrosine hydroxylase; DBH: dopamine-beta-hydroxylase; PNMT: phenylethanolamine N-methyltransferase; MAO: monoamine oxidase; COMT: catechol-O-methyltransferase; HVA: homovanillic acid; VMA: 3-methoxy-4-hydroxymandelic acid; MHPG: 3-methoxy-4-hydroxy-phenylglycol; D1AS1: dopamine receptor 1A silencer 1; DRD1A: dopamine receptor 1A; AC: adenylyl cyclase; and cAMP: cyclic adenosine monophosphate.

**AP-2β regulation of serotonergic transmission**

AP-2β controls multiple key genes in the serotonergic (5-HT) pathway (Fig. 4) and has been shown to enhance serotonergic turnover and transmission in the brain [24], perhaps by increasing serotonin availability in the synaptic cleft. Two key genes in the serotonergic system have been shown to be negatively regulated by AP-2β: MAO-A [28, 91–93] and 5-HTT [19, 20, 101]. 5-HTT transports 5-HT into presynaptic where it is degraded by MAO. Thus, inhibiting 5-HTT and MAO genes by AP-2β may result in increased serotonin levels in the synaptic cleft and serotonergic transmission [24, 25]. In addition, AP-2β has a binding site on tryptophan hydroxylase (TPH), aromatic l-Amino acid decarboxylase (AADC) as well as rat 5-Htr2 and human 5HT3R [62, 102–107]; yet, its regulatory effect on these genes is still unknown. Given the positive correlation between AP-2β and serotonergic activity in the brainstem [24, 25], it is reasonable to suggest that AP-2β may enhance the expression of TPH and AADC as well, although studies are needed to confirm this suggestion.

The vesicular monoamine transporter 2 gene (VMAT2), a key regulator of the monoamine neurotransmitters’ availability in the synaptic cleft, has a putative AP-2β binding site in its promoter region [23]. However, the regulatory effect of AP-2β on this gene
has not been fully explored. In an attempt to explore this, using Drosophila melanogaster, our group has shown that the Drosophila analogue of TFAP2B, TfAP-2, positively regulates the expression levels of Drosophila VMAT2, Vmat, and activates octopaminergic neurons (analogous to human noradrenergic neurons) [81]. Considering that TFAP2B is conserved in Drosophila (TfAP-2) and there is a high homology between Drosophila Vmat and human VMAT2 (weighted score 14/15) [108, 109], AP-2β might also activate VMAT2 in humans. Consistent with this suggestion is the observations that, similar to AP-2β [24, 25], activation of VMAT2 enhances monoaminergic transmission in the synaptic cleft, not to mention that VMAT2 dysregulation results in disorders that are also associated with TFAP2B, namely depression [110], AD [111], alcoholism [112] and obesity [113, 114]. Altogether, more research on AP-2β effects on human VMAT2, for instance in human neuronal cell culture, are warranted.

Taken together, AP-2β can modulate both arms of monoaminergic neurotransmitter systems, by controlling the key genes in catecholaminergic and serotonergic transmission, indicating its role as a key regulator of monoaminergic neurotransmitter systems and its importance for better understanding and management of MNDS.

**TFAP2B polymorphisms**

The TFAP2B gene is located on chromosome 6p12-p21, and it has eleven exons with a size of 29,910 bases [115, 116]. TFAP2B has many polymorphic regions that affect mostly its transcriptional activity rather than its protein structure [29, 34, 117]. This in turn influences the expression of its target genes in the monoaminergic neurotransmitter systems. Consequently, TFAP2B functional polymorphisms have been associated with different MNDS. To date, three functional polymorphisms of TFAP2B are known to be associated with MNDS. One is located in intron 1, in which polymorphic regions (SNP at intron 1 + 774T/G and a nearby variable number tandem repeat, VNTR, allele), have been shown to postively regulate TFAP2B transcriptional activity,
enhancing its expression. Subjects who carry the disease-related alleles (S-allele: T-nucleotide for SNP, nine repeats for VNTR) show higher expression of $TFAP2B$, which is associated with a higher risk for T2D and a lower risk for depression [34, 36, 102, 118].

The second polymorphism is located in intron 2 in a polymorphic region [CAAAA] close to the 3’-splice site of exon 2 between nucleotides 12593 and 12612 [27, 51]. Repeats of this sequence in variable regions suggest its important role in functional polymorphisms [25, 27, 60]. Interestingly, the 5-repeat alleles of indel intron 2 of $TFAP2B$ have been shown to increase the expression of $TFAP2B$ [19]. The intron 2 polymorphism is associated with adiposity, neonatal temperament and anxiety-related personality traits [19, 26, 27, 29]. Strikingly, there is significant linkage disequilibrium between the polymorphisms of intron 1 and intron 2 [27, 29, 119], indicating that their association is not by chance. This suggests that the associations observed with intron 2 polymorphisms are most likely a result of the functional polymorphism in intron 1 [28].

The third $TFAP2B$ polymorphism, rs987237, is located in intron 3 and has three different genotypes, AA, AG and GG that are associated with obesity, BMI, waist circumference and differential effects on weight loss [120–123]. Stocks et al. have suggested that the $TFAP2B$ rs987237 variant may be linked to enhanced transcription of this transcription factor since it is also in complete linkage disequilibrium with intron 1 [28].

Overall, three $TFAP2B$ polymorphisms have been shown to mostly enhance its transcription activity. This in turn affects the expression of the key genes in the monoaminergic neurotransmitter systems that have putative binding sites for AP-2β.

**Monoamine neurotransmitter disorders associated with $TFAP2B$ dysregulation and possible underlying mechanisms**

**Obesity and type 2 diabetes (T2D)**

Studies have shown that $TFAP2B$ polymorphisms of intron 1, 2 & 3 that lead to higher expression of $TFAP2B$, are associated with reward fixation, insulin resistance, T2D and adiposity, lipid droplet biogenesis as well as eating disorders [29, 34, 36, 124–128]. GWAS studies have indicated an association of $TFAP2B$ rs987237 within intron 3 with obesity, BMI and waist circumference in women [120, 129, 130]. There is, however, a debate whether rs987237 is associated with improved weight loss, depending on the genotype (AA, GG or AG) [120–122] and the type of diet (high/low-fat diet or high/low protein diet) [120, 131].

The mechanisms underlying AP-2β-induced insulin resistance and adiposity are rather unclear. Several studies have attributed the role of AP-2β in insulin resistance and adiposity to its regulatory effect on genes that encode adipocytokines, which have AP-2β binding sites in their promoters. For instance, $TFAP2B$ overexpression has been shown to inhibit the expression of adiponectin and leptin but also enhance the expression of interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP) and tumour necrosis factor-alpha (TNF-alpha) [34, 124, 132–135]. However, Tsukada et al. have demonstrated that overexpressed $TFAP2B$ has no effect on most adipocytokines like adiponectin, leptin and IL-6 [34]. Additionally, a study by Nordquist et al. have shown no association of adiponectin levels to insulin resistance or to the $TFAP2B$ polymorphism [29]. Furthermore, AP-2β has been reported to enhance glucose uptake (enhancing the translocation of the glucose transport 4, GLUT4) but also reduce insulin sensitivity through both, repressing the expression of insulin receptor substrate 1 (IRS-1) and lipid accumulation [29, 31, 36, 133, 134]. The enhanced glucose uptake effect, however, is not in line with the inhibitory effect of AP-2β on adiponectin and leptin, mentioned above since higher adiponectin and leptin have been shown to enhance glucose uptake [136, 137]. Given such discrepancies, it is reasonable to suggest another pathway by which AP-2β contributes to obesity and T2D, possibly through monoaminergic neurotransmitter systems.

Many research studies have revealed that polymorphisms or overexpression of $TFAP2B$ contribute to eating disorder-related behaviour through catecholamine-induced orexigenic signals [78, 79]. In terms of glucose uptake and insulin resistance, AP-2β augments norepinephrine availability [24, 25], and elevated norepinephrine has been reported to increase glucose uptake and transport in adipose tissue [138, 139]. Moreover, AP-2β increases both norepinephrine and epinephrine levels [24, 25], both of which can contribute to insulin resistance and obesity [140–145]. Furthermore, AP-2β upregulates $PNMT$ [46, 86–88], and upregulated $PNMT$ has been associated with elevated epinephrine and reduced circulating leptin levels [146], both of which can give rise to obesity [141, 142, 146].

The association of $TFAP2B$ with obesity-related disorders might also be linked to its repression effect on 5-HTT. First, 5-HTT re-uptakes 5-HT from the synaptic cleft into the presynaptic neurons. As we mentioned previously, AP-2β represses the expression of 5-HTT [19, 20, 101] and 5-HTT gene promoter methylation is associated with reward and eating behaviour as well as human obesity [147] and suppression of 5-HTT, by hypermethylation, in humans is associated with a high prevalence of obesity [148].
Alcoholism
That dysregulation of monoamine neurotransmitters contributes to the development of alcoholism is well known. Reports have indicated that TFAP2B polymorphism in the intron 1, which can enhance AP-2β transcription, is associated with severe alcoholism in women [28]. This association has been linked to the effect of AP-2β on several targets in the monoaminergic system. AP-2β lowers the levels of MAO and lowered levels of MAO are linked to alcoholism [28, 149–151]. AP-2β activation of dopamine-beta-hydroxylase (DBH) [82] may also contribute to alcoholism, since in alcohol-dependent persons, DBH is hypomethylated and its enzyme is more active, resulting in a reduction of dopamine levels [152, 153]. However, inhibition of DRD1 or DRD1 KO mice has been shown to reduce alcohol-seeking behaviour [154–157], suggesting that AP-2β-induced alcohol intake might be independent of its repressing effect on DRD1 [94].

Moreover, AP-2β-enhanced serotonergic transmission may also contribute to alcohol abuse, perhaps through inhibition of 5-HTT [19, 20, 101] and lowering MAO [28, 91–93]. In agreement with this notion, increased serotonin levels or 5-HTT KO mice have been found to trigger alcoholism [158–160], and MAO-A methylation is associated with alcoholism in women [161]. Furthermore, alcohols have higher levels of both, the transcript and protein of tryptophan hydroxylase, TPH [162], the rate-limiting enzyme in serotonin synthesis, which has a binding site for AP-2β in its promoter [107]. Increased levels of TPH have been reported to enhance serotonin levels [163].

Anxiety and depression
TFAP2B intron 2 polymorphisms are associated with low anxiety [26, 27, 93], and its intron 1 polymorphism, which enhances its expression, protects against the risk of depression in patients with attention deficit hyperactivity disorder [102]. However, when psychosocial adversity is considered, individuals with TFAP2B intron 2 polymorphisms who are homozygous for the short TFAP2B allele exhibited higher depression scores [117].

This association might be ascribed to the AP-2β regulatory effect on the monoaminergic neurotransmitters in the brain. Mechanistically, AP-2β inhibits 5-HTT expression [19, 20, 101] and inhibition of 5-HTT, by SSRIs for instance, leads to increased serotonin, which alleviates anxiety and depression [164]. Moreover, AP-2β reduces MAO levels [28, 91–93], which may also contribute to reduced anxiety and depression. In agreement with this possibility, deficiency of MAO-A or MAO-B leads to reduced anxiety-like behaviour in mice, as well as inhibition of MAO-A reduces depression in mice, and likewise, drugs that inhibit MAO-B reduce depression as well [165, 166]. Interestingly, MAO inhibitors enhance the levels of noradrenaline and serotonin levels in the brain to alleviate anxiety [167] and depression [168]. In consonance with these effects, AP-2β enhances noradrenaline and serotonin transmission [24], both of which have been reported to exert anxiolytic and antidepressant effects [9, 169–171].

Since certain antidepressant/anxiolytic drugs, e.g. citalopram (SSRI) and imipramine (TCA), have been reported to modulate the levels of AP-2β in the brainstem of the rat [24, 38, 84], probably due to its transcriptional regulation of the key targets in monoaminergic neurotransmitter systems, future clinical anxiolytic/antidepressant drug development should monitor the level of AP-2β for better management and/or prevention of depression and anxiety.

Antisocial behaviour
Antisocial behaviour in children and adolescents refers to a heterogeneous set of actions outside the norms of society, including aggression, impulsive behaviour and criminal acts, which are linked to monoaminergic neurotransmitter systems [172–175]. TFAP2B has been associated with aggression in fruit flies and humans, as well as with general antisocial behaviour in humans [27, 28, 81, 176]. However, the TFAP2B signalling mechanisms that underlie such association have not been fully elucidated. The repressing effect of AP-2β on monoamine-degrading enzymes, such as COMT and MAO might explain such an association since several reports have revealed that lowered expression of MAO-A, or MAO-A KO mice, as well as lower activity of COMT or COMT-deficiency in
mice are associated with higher aggression [177–182]. Furthermore, activation of DBH expression by AP-2β may also play a part in provoking high aggression. Activation of DBH enhances the conversion of dopamine to adrenaline and it has been reported that higher adrenergic signalling provokes aggression [183], and DBH KO mice have lower levels of aggression [184], all linking AP-2β-mediated higher aggression to enhanced adrenergic signalling.

Nevertheless, the AP-2β association with higher aggression might be independent of its enhancement effect on serotonergic signalling, specifically, its repressing effect on 5-HTT. This is because several preclinical and clinical studies have indicated high levels of serotonin and lower expression or blocking of 5-HTT or knocking out 5-HTT in mice lead to reduced aggression outbursts and violent behaviour [185–188], an effect opposite to that of AP-2β. It would be interesting to investigate the association of TFAP2B polymorphisms and their interaction with key monoamine neurotransmitter genes to aggression and antisocial behaviour.

Alzheimer’s disease (AD)
While genetic variants of TFAP2B have been suggested to play a role in resilience to AD [189], increased AP-2β has been shown to bestow a neuroprotective effect in AD due to the AP-2β-enhancing effect on the expression of apolipoprotein E (apoE), an important protective protein in AD pathogenesis [32, 190]. The effects of AP-2β on catecholamines might also contribute to its protective effect in AD. Firstly, lowered catecholamine levels contribute to the development and pathogenesis of AD [191–193] and, by the same token, AP-2β has been shown to increase catecholamine signalling in the brain [24, 46, 86–88]. AD is also associated with lower levels of DBH and PNMT [194–198], which both are activated by AP-2β [46, 86–88]. In addition, COMT and MAO-B levels are higher in AD [192, 199–201], and both are lowered by AP-2β [21, 92, 93]. Supporting this notion, COMT and MAO inhibitors have been repurposed for the treatment of AD [202–204]. Secondly, AP-2β enhances serotonin activity in the brain which might add further protective effects in AD. Consistent with this extrapolation is the observation that reduced serotonin levels in the brain can enhance the risk for AD [205], providing the rationale for SSRI use to delay the onset of AD [206]. Taken together, it might be suggested that, through its enhancing catecholaminergic and serotoninergic activities, AP-2β may exert a protective role in AD. Thus, elucidating the association of TFAP2B polymorphisms and their interactions with COMT, MAO, to AD could unveil a potential biomarker for early diagnosis and management of AD.

Neuroblastoma
Transcription factors serve as essential regulators of cell development, proliferation and differentiation; consequently, dysregulation of them brings about oncogenic transformation and cancers [207, 208]. Neuroblastoma is an embryonal pediatric malignant tumour originating from the sympathetic nervous system and characterized by extremely low noradrenergic neuronal differentiation [33]. However, the molecular mechanisms underlying lowered neuronal differentiation in neuroblastoma are still under investigation.

Recent studies have revealed an important role of AP-2β in the pathogenesis and progression of neuroblastoma [33, 37, 209, 210]. Thorell et al. have identified TFAP2B as a potential tumour suppressor gene in neuroblastoma [210]. Ikram et al. have also indicated that low AP-2β expression results in lower noradrenergic neuronal differentiation and is thereby significantly associated with poor prognostic markers and unfavourable patient outcomes [33]. In contrast, induction of AP-2β expression has been found to impair tumour cell proliferation and slow tumour progression by enhancing both differentiation of noradrenergic neurons as well as noradrenergic signalling through increased expression of TH and DBH [33]. In addition to its effects on sympathetic neurons, AP-2β has been demonstrated to enhance retinoic acid (RA) responsiveness, which potentiates neuronal differentiation and therefore is used in neuroblastoma therapy [33].

 Altogether, AP-2β is associated with certain MNDS, although the underlying mechanisms are not fully elucidated. As we mentioned above, the underlying mechanisms for this association might be linked to AP-2β regulatory effects on key genes of monoaminergic neurotransmitters. However, further preclinical studies investigating the molecular mechanisms underlying AP-2β associated MNDS, e.g. manipulating the expression of TFAP2B in neuronal cell culture or rats’ models of MNDS and examining the levels of the key enzymes of monoaminergic neurotransmission, are warranted.

AP-2β as a biomarker and a potential therapeutic target
AP-2β as a biomarker
Transcription factors are currently widely used as diagnostic biomarkers for the early detection of several diseases [211–213]. A wide range of brain-related disorders and cancers are accompanied by alterations in the levels and activity of TFAP2B/AP-2β, which underscores its diagnostic importance for such diseases. TFAP2B overexpression, for instance, has been implicated not only as a protective or favourable prognostic factor in several cancers like breast, renal cell, cervical and
endometrial cancers but also as a poor prognostic factor in thyroid cancer and lung adenocarcinoma [214–225] (See Table 1).

Along the same line, AP-2β might also constitute a diagnostic biomarker for other MNDs. For example, while TFAP2B/AP-2β overexpression has already been suggested as a favourable prognostic marker in neuroblastoma[33, 210], it might further be considered as a biomarker for other MNDs where TFAP2B/AP-2β overexpression is implicated, such as alcoholism, obesity, T2D and aggression. Nevertheless, clinical studies are needed to address its specificity and characterize its validity as a biomarker for the early diagnosis of these disorders.

**AP-2β as a potential therapeutic target**

In the last decade, targeting transcription factors with selective therapeutic agents has gained growing interest because transcription factors act as on/off switches of gene expression, a process that leads to neurological disorders and cancers when disrupted. In this context, clinical reports have highlighted the potential of AP-2β as a therapeutic target for specific cancers such as lung adenocarcinoma [216], renal cell tumorigenesis [220], and breast [221] and endometrial cancers [217].

TFAP2B/AP-2β might also be considered an interesting therapeutic target for the management of specific MNDs, where its synergistic effects on multiple targets may be beneficial for the treatment or prevention of complex diseases. This concerns specifically the neurometabolic disorders, such as obesity and type 2 diabetes, that are characterised by widespread systemic alterations through diverse factors including, behavioural, neural, hormonal, adipose and intestinal along with the involvement of different mediators such as monoamine neurotransmitters, insulin and adipocytokines. In this regard, researchers have emphasized the importance of AP-2β as a promising drug target for the prevention and treatment of obesity and T2D [34–36]. AP-2β can target multiple features of obesity and T2D centrally and peripherally by modulating key-obesity linked genes such as IRS-1, GLUT4, adipocytokines related genes, as well as catecholaminergic and serotoninergic genes involved in reward, consummatory behaviour and insulin resistance (Table 3). Some of these genes are, intriguingly, recognized as therapeutic targets of several drugs used for obesity-linked diseases.

A second possible application of AP-2β as a therapeutic target is in the treatment of neuroblastoma [37], where the benefits of treatment success could outweigh the possible side effects. As mentioned previously, lower expression of TFAP2B is associated with a poor prognosis of neuroblastoma since patients whose tumour cells have lowered TFAP2B showed poor treatment outcomes [33]. In contrast, elevated TFAP2B has been reported to improve patient outcomes [33] by enhancing noradrenergic neuronal differentiation through different target genes in monoaminergic transmission [33, 210] and subsequently repress the progression of neuroblastoma. Most importantly, induction of TFAP2B expression by tetracycline has already been successfully employed to impair tumour cell proliferation and slow neuroblastoma progression [33]. Collectively, boosting AP-2β levels might represent a potential therapeutic approach, perhaps in combination with other anti-neuroblastoma therapies, to treat neuroblastoma, possibly through a

| Table 3 Summary of the mechanisms underlying AP-2β effects, and potential therapeutic interventions for specific monoamine neurotransmitter disorders (MNDs) |
|---|
| Monoamine Disorder | AP-2β effect | AP-2β target genes | Affected modulators | Possible pharmacological intervention | Possible therapeutics |
| Obesity and Type 2 diabetes | Induction | TH (+) [33, 82, 89] DBH (+) [33, 82, 89, 90] PNMT (+) [46, 86–88] S-HITT (–) [19, 20, 101] VMAT2 (?) [23] DRD1α (–) [94] MAO (–) [28, 91–93] COMT (–) [21, 92] Adipokines-related genes (±) [34, 123, 131, 133–135] IRS-1(–) [134] | Norepinephrine (+) Epi-nephrine (+) Dopamine Serotonin (±) Adipocytokines (±) Insulin (–) | Inhibition of AP-2β Peptide inhibitors |
| Neuroblastoma | Suppression | TH (+) [33, 82, 89] DBH (+) [33, 46, 82, 89, 90] PNMT (+) [46, 86–88] | Norepinephrine (+) Epi-nephrine (+) Dopamine | Activation of AP-2β AP-2β analogue or activators |

TH tyrosine hydroxylase, PNMT: phenylethanolamine-N-methyltransferase, MAO: monoamine oxidase, S-HITT: serotonin transporter, DRD1α: dopamine receptor D1A. VMAT2: Vesicular monoamine transporter 2, DBH: dopamine-beta-hydroxylase, IRS-1: Insulin receptor substrate 1; COMT: catechol-O-methyltransferase.
localized drug delivery, which could minimize peripheral undesired effects. This is supported by the fact that Tri-chostatin A, a potential drug used for neuroblastoma, has been shown to augment monoamine pools by inhibiting COMT and MAO-A genes [226], a mechanism similar to that of AP-2β.

Like other drug targets at the transcription level, off-target effects could pose a substantial challenge. AP-2β has been reported to modulate multiple key genes within and outside the monoaminergic neurotransmitter systems, suggesting off-target effects. Consequently, such ubiquitous off-target effects might limit its potential as a therapeutic target due to the lack of specificity and the risk of adverse effects.

**Targeting AP-2β (druggability), challenges and future insights**

Until recently, transcription factors had been considered very challenging targets (undruggable) since transcription factors lack obvious druggable pockets and the transcription process is carried out in the nucleus; therefore, the therapeutic agent should have the appropriate physicochemical properties to cross many biological barriers and reach the nucleus with sufficient concentration. Moreover, many crucial components involved in the transcription process do not have the enzymatic activity adequate for pharmaco-chemical interventions [227, 228].

So far, manipulation of transcription factor activity at protein–protein interaction levels has been successfully implemented and a few drugs have been approved for various disorders [227, 229]. As mentioned previously, several proteins have been reported to modulate the levels and activity of AP-2β (see Table 2). Such modulator proteins can be targeted to regulate TFAP2B/AP-2β at different levels: at transcription, post-translation or the DNA-binding site (Fig. 5). Yet, potency and selectivity may pose a substantial issue because targeting these proteins can elicit a chain of inadvertent adverse effects since they are also involved in diverse biological processes and regulate other AP-2 transcription factors [42].

---

**Fig. 5** Possible sites and targets that can be potentially exploited to modulate AP-2β activities and/or levels. One proposal for modulating AP-2β is through protein–protein interactions whereby co-activators/suppressors bind to the transactivation domain and modify AP-2β transcription activity and DNA-binding activities, as indicated within the yellow square. Inducing degradation of AP-2β could be achieved through designing peptide inhibitors binding selectively to its transactivation domain to form a non-functional complex or by enhancing PKD phosphorylation of AP-2β [71] or by developing specific monoclonal antibodies that can bind and inactivate AP-2β. By contrast, enhancing AP-2β activity could be feasible by designing artificial transcription factor analogues (TFA) that can act as AP-2β agonists. Some monoaminergic drugs, such as phenelzine and citalopram, also have been shown to alter the brain levels of AP-2β [38, 39] while tetracycline induces its gene expression[33]. KCTD1 & KCTD15: potassium channel tetramerization domain 1 & 15; UBC9: ubiquitin carrier protein 9; HIF-2α: hypoxia-inducible factor-2alpha; YEATS4: YEATS domain-containing protein 4; CITED2 & 4: Cpb/p300-interacting transactivator 2 & 4; PKD: the protein kinase D; DAG: diacylglycerol. The Figure was created with BioRender.com
Despite these challenges, in the last decade, advances in pharmacological interventions have facilitated the druggability of transcription factors by specifically modulating their DNA-binding and transcription regulation activities at specific pockets. Interestingly, such pharmacological strategies have been successfully applied preclinically [228, 230–234] and clinically [235, 236], and at least 10% of drugs obtained FDA approval [208, 228, 237, 238]. Moreover, a recent article in Nature Reviews Drug Discovery by Henley et al. has discussed the renewed interest in the advent of pharmacological interventions for targeting transcription factors [208]. Currently, about ten drugs acting on transcription factors are in clinical trials [208], indicating a driving trend toward targeting transcription factors.

For example, inducing protein degradation of the transcription factor can be driven by exploiting its transactivation domain. Binding to this part with a specific peptide can form a non-functional complex for degradation. Such technology has facilitated abolishing of transcription factor activity by designing peptide inhibitors, also known as peptide therapeutics [233] that binds to the transactivation domain of the transcription factor and thereby hinder its interactions with other proteins and ultimately induce its degradation (Fig. 5). An interesting example in this context is YK-4-279, which peptide inhibitor that binds to the oncogenic transcription factor EWS-FLI1 to inhibit its activities. YK-4-279 is used to treat Ewing sarcomas [231, 239].

In parallel, providing the basic knowledge of its domain structure and binding sites, direct inhibition of AP-2β, by peptide inhibitors capable of selectively binding to its transactivation domain and inducing its degradation could be attractively applicable. Such specific peptide inhibitors could interfere with the dynamic of AP-2β protein–protein interactions and subsequently block its transcriptional activity on the target genes. This represents an interesting therapeutic approach for the management of obesity and related neurometabolic disorders where higher AP-2β levels are implicated.

On the other hand, mimicking transcription factor activity has been made feasible, especially in cancer and neurometabolic disorders. Many artificial transcription factors, also called transcription factor analogues (TFAs), have been successfully developed for several cancers and loss-of-function mutations to restore the overall functions of the transcription factors [231]. Dimethyl fumarate (DMF), for example, is an Nrf2 activator, which is FDA-approved for multiple sclerosis (MS) [237]. In a similar vein, induction of AP-2β-related transcriptional effects on its target genes could be achieved by designing an AP-2β analogue with sufficient selectivity and potency (Fig. 5). Such AP-2β agonists could mediate effects similar to that of AP-2β and thereby be used in disorders where higher AP-2β is therapeutically advantageous such as in neuroblastoma. Nevertheless, full characterization of the protein crystal structure of AP-2β is a prerequisite for developing such therapeutic agents.

**Concluding remarks**

AP-2β is a central regulator of monoamine neurotransmitters and its dysregulation is associated with MNDs. The underlying mechanisms for its associated MNDs could be linked to its regulatory role in monoaminergic transmission, yet more studies are recommended. For example, knockout/overexpression of TFAP2B in rat models of MNDs and examining the expression of the key monoaminergic genes can help clarify the molecular pathogenesis of the associated MNDs. Moreover, the molecular functions of AP-2β within the monoaminergic systems underline its importance as a promising biomarker for the early diagnosis of relevant MNDs. Given its effect on multiple targets within and outside monoaminergic systems, AP-2β could be considered a dirty drug target due to the odds of having adverse effects. Nevertheless, several dirty drugs that aim for multiple targets at once are clinically effective in the treatment of complex diseases [240, 241], which might underscore the therapeutic potential of the AP-2β for complex MNDs like obesity and neuroblastoma. Future drug development targeting monoaminergic systems could take advantage of monitoring the AP-2β levels during clinical studies for better management and treatment of MNDs.

**Abbreviations**

CNS: Central nervous system; PNS: Peripheral nerve system; MNDs: Monoamine neurotransmitter disorders; DA: Dopamine; NA: Noradrenaline; 5-HT: Serotonin; T2D: Type 2 diabetes; AD: Alzheimer’s disease; TCA: Tricyclic antidepressants; SSRIs: Selective serotonin reuptake inhibitors; SNRIs: Serotonin and norepinephrine reuptake inhibitors; MAOIs: Monoamine oxidase inhibitors; COMTIs: Catechol-O-methyltransferase inhibitors; AP-2β: Transcription factor activating protein 2 beta; 3-HT: Serotonin transporter; DBH: Dopamine-beta-hydroxylase; VMAT2: Vesicular monoamine transporter 2; WWOX: WWOX Domain Containing OxidoReductase; GREB1: Growth Regulating Estrogen Receptor Binding 1; CDH2: Cadherin-2; HPSE: Heparanase; IGSF11: Immunoglobulin Superfamily Member 11; BOFS: Branchio-ocular-facial syndrome; COL2A1: Core promoter of type II collagen; HMOX1: Heme Oxygenase 1; IRS-1: Insulin resistance substrate 1; PKC: Protein kinase C; PKA: CAMP-dependent protein kinase A; KCTD1: The potassium channel tetramerization domain 1; KCTD15: Potassium channel tetramerization domain 15; PKD: Protein kinase D; HIF-2α: Hypoxia-inducible factor-Zalpna; CITED2: Cbp/p300-interacting transactivator 2; CITED4: Cbp/p300-interacting transactivator 4; YEATS4: YEATS Domain-containing protein 4; MYC: MYC Proto-Oncogene, bHLH transcription factor; TP53: Cellular tumor antigen p53; UBC: Ubiquitin carrier protein 9; UBE2I: Ubiquitin conjugating enzyme E2 I; ST14: Synaptotagmin-4; TH: Tyrosine hydroxylase; PNMT: Phenylethanolamine N-methyltransferase; MAO-A: Monoamine oxidase-A; DRD1L: Dopamine receptor D1A; AC: Adenylyl cyclase; cAMP: Cyclic adenosine monophosphate; HAV: Homovanillic acid; MGPG: 3- Methoxy-4-hydroxy-phenylgly; TPH: Tryptophan hydroxylase; AADC: Aromatic L-amino acid decarboxylase; VMAT2: Vesicular monoamine transporter 2 gene; IL-6:
Acknowledgements

We thank Nour Aldin Kahlous, a Ph.D. student at the department of Cell and Molecular Biology, Computational Biology and Bioinformatics, Uppsala University, for his valuable suggestions on the druggability part of this review.

Author contributions

MHA-S, MN, MW contributed to the conception of the manuscript. The first draft of the manuscript was written by MHA-S and MN. LEC, MMA, MJW, MR-A, JM and HBS commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by Uppsala University. HBS is supported by the Swedish Research Council, The Swedish Brain Research Foundation and the Novo Nordisk Foundation.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, PO. Box 593, 751 24 Uppsala, Sweden. 2Department of Immunology, Uppsala University, Dag Hammarskjölds väg 20, 751 85 Uppsala, Sweden. 3Present Address: Department of Medical Sciences, Uppsala University, BMC, Husargatan 3, 750 03 Uppsala, Sweden.

Received: 20 June 2022 Accepted: 28 August 2022 Published online: 08 September 2022

References

1. Kurian MA, Gissen P, Smith M, Heales SJR, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721–33.
2. Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders—an expanded range of neurological syndromes. Lancet Neurol. 2015;14:576–84.
3. World Health Organization (WHO). Leading causes of death and disability worldwide. 2000–2019. https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019. 2020.
4. Hauser TU, Eldad E, Purgi N, Moutoussis M, Dolan RJ. Distinct roles of dopamine and noradrenaline in incidental memory. J Neurosci. 2019;39:7715–21.
5. Narvaez R, de Almeida RMM. Aggressive behavior and three neurotransmitters: dopamine, GABA, and serotonin—a review of the last 10 years. Psychol Neurosci. 2014;7:601–7.
6. See D, Patrick CJ, Kenneally PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Beh. 2008;13:383–95.
7. Hull EM, Muskamp JW, Sato S. Dopamine and serotonin: Influences on male sexual behavior. Physiol Behav. 2004;83:291–307.
8. Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatric Dis Treat. 2011;7:9–13.
9. Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat. 2016;12:541–57.
10. González-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res. 2008;172:603–23.
11. Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer. 2011. https://doi.org/10.1038/sj.bjc.6605996.
12. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004. https://doi.org/10.1016/j.neuro.2004.05.019.
13. Von Kleist L, Michaelis S, Bartho K, Grebner O, Schlief M, Dreger M, et al. Identification of Potential off-target toxicity liabilities of catechol-O-methyltransferase inhibitors by differential competition capture compound mass spectrometry. J Med Chem. 2016. https://doi.org/10.1021/acs.jmedchem.5b01970.
14. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019;12:117864691987392–117864691987392.
15. Low Y, Setia S, Lima G. Drug–drug interactions involving anti-depressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567–80.
16. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9:41–6.
17. Ramsay RR, De Deurwaerdère P, Di Giovanni G. Updating neuropharmacology and neurophysiology of monoaminergic systems. Br J Pharmacol. 2016;173:2065–2065.
18. Cohen LJ, Sclar DA. MAOIs: issues in treatment adherence and rates of treatment failure. J Clin Psychiatry. 2013;74:26367.
19. Ivorra JL, D’Souza UM, Jover M, Annaz MJ, Williams BP, Henry SE, et al. Association between neonatal temperament, SLC6A4, DRD4and a functional polymorphism located in TRAP2B. Genes Brain Behav. 2011;10:570–8.
20. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78:815–26.
21. Tenhunen J. Characterization of the rat catechol-O-methyltransferase gene proximal promoter: identification of a nuclear protein-DNA interaction that contributes to the tissue-specific regulation. Lymphoch: Mary Ann Liebert, Inc.; 1996.
22. Greco D, Zellmer E, Zhang Z, Lewis E. Transcription factor AP-2 regulates expression of the dopamine beta-hydroxylase gene. J Neurochem. 1995;65:510–6.
23. Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M, et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 2000;14:2459–65.
24. Damberg M, Berggärd C, Farde L, Svedlov GC, Jonsson EG. Transcription factor AP-2β genotype, striatal dopamine D2 receptor density and cerebrospinal fluid monoamine metabolite concentrations in humans. J Neural Transm. 2004. https://doi.org/10.1007/s00702-003-0097-4.
25. Damberg M, Berggärd C, Mattila-Evensd M, Rylander G, Forslund K, Garpenstrand H, et al. Transcription factor AP-2β genotype associated with anxiety-related personality traits in women: a replication study. Neuropsychobiology. 2003;48:169–75.
26. Damberg M, Garpenstrand H, Alfredsson J, Ekblom J, Forslund K, Rylander G, et al. A polymorphic region in the human transcription factor AP-2β gene is associated with specific personality traits. Mol Psychiatry. 2005;10:220–4.
27. Nordquist N, Göktürk C, Comasco E, Nilsson KW, Orelend L, Hallman J. Transcription factor AP2 beta involved in severe female alcoholism. Brain Res. 2009;1305:520–4.
29. Nordquist N, Göktürk C, Comasco E, Eensdo E, Merenäkk L, Veidebaum T, et al. The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. Obesity. 2009;17:1762–7.

30. Damberg M, Garpenstrand H, Hallman J, Oreland L. Genetic mechanisms of behavior—don’t forget about the transcription factors. Mol Psychiatry. 2001;6:503–10.

31. Tao Y, Maegawa H, Ugi S, Ikeda K, Nagai Y, Egawa K, et al. The transcription factor AP-2β causes cell enlargement and insulin resistance in ST3-L1 adipocytes. Endocrinology. 2006;147:1685–96.

32. Rossello XS, Igbaovu U, Weisman GA, Sun GY; Wood WG. AP-2 regulates amyloid β-peptide protein stimulation of apolipoprotein e transcription in astrocytes. Brain Res. 2012;1444:87–95.

33. Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, et al. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol Oncol. 2016;10:344–59.

34. Albuquerque D, Nóbrega C, Rodríguez-López R, Manco L. Association study of common polymorphisms in MSRA, TFAP2B, MCHR, NR0N3, PPARGC1A, TMEM18, SEC16B, H6OXS and OLFM4 genes with obesity-related traits among Portuguese children. J Hum Genet. 2014;59:307–13.

35. Maeda S, Tsukada S, Maegawa H, Hashiguchi H, Kawamura M, Noda N, et al. Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. J Hum Genet. 2005;50:283–92.

36. Jansky S, Sharma AK, Körber V, Quintero A, Toprak UH, Wecht EM, et al. Single-cell transcriptional analyses provide insights into the developmental origins of neuroblastoma. Nat Genet. 2021;53:683–93.

37. Berggård C, Damberg M, Oreland L. Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram. BMC Pharmacol. 2005. https://doi.org/10.1186/1471-2210-5-1.

38. Berggård C, Damberg M, Oreland L. Chronic citalopram treatment reduces ependymal expression of the distal nephron in the mammalian kidney. Nat Commun. 2022;13:1–18.

39. Damberg M. Transcription factor AP-2 and monoaminergic functions in the central nervous system review. J Neural Transm. 2005;112:1281–96.

40. Roeslers WJ, Vandenbark GR, Hanson RW. Cyclic AMP and the induction of eukaryotic gene transcription*. J Biol Chem. 1988;263:9063–6.

41. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinger U, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.

42. Pichler K, Warner K, Magrane M. SPIN: submitting sequences determined at protein level to UniProt. Curr Protoc Bioinform. 2018. https://doi.org/10.1002/cpbi.052.

43. Moser M, Rüschoff J, Buettner R. Comparative Analysis of AP-2 Alpha and AP-2 Beta Gene Expression During Murine Embryogenesis. Dev Dyn. 1997;208:115–24.

44. Lamontagne JO, Zhang H, Zaid AM, Strittmatter K, Rocha AD, Williams T, et al. Transcription factors AP-2α and AP-2β regulat distinct segments of the distal nephron in the mammalian kidney. Nat Commun. 2022;13:1–18.

45. Berggård C, Damberg M, Oreland L. Chronic citalopram treatment induces time-dependent changes in the expression and DNA-binding activity of transcription factor AP-2 in rat brain. Eur Neuropsychopharmacol. 2003;13:1–17.

46. Mitchell PJ, Wang C, Tjian R. Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell. 1987;50:647–61.

47. Wang HV, Vaupek K, Buettner R, Rosserhoff AK, Moser M. Identification and embryonic expression of a new AP-2 transcription factor, AP-2e. Dev Dyn. 2004;231:128–35.

48. Eckert D, Buhl S, Weber S, Jäger R, Schorle H. The AP-2 family of transcription factors. Genome Biol. 2005;6:246–246.

49. Hilger‑Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of transcription factors. Gene. 2000;260:1–12.

50. Moser M, Dahmen S, Kluge R, Gröne H, Dahmen J, Kunz D, et al. Terminal renal failure in mice lacking transcription factor AP-2β. Lab Investig. 2003;83:571–8.

51. Moser M, Picherer A, Roth C, Becker J, Mucher G, Zerres K, et al. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2β. Genes Dev. 1997;11:1938–1938.

52. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ. Transcription factor AP-2 is essential for cranial closure and craniofacial development. Nature. 1996;381:235–8.

53. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–9.

54. Duvaud S, Gabelia C, Lisacell E, Stockinger H, Ioannidis V, Durin C. Expasy, the Swiss Bioinformatics Resource Portal, as designed by its users. Nucleic Acids Res. 2021;49:W216–27.

55. Nelm Bl, Labosky PA. Genes, transcriptional control of neural crest development. Dev Biol. 2010;1:11–27.

56. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell. 1987;51:221–60.

57. Rogers EW, Vandenbark GR, Hanson RW. Cyclic AMP and the induction of eukaryotic gene transcription*. J Biol Chem. 1988;263:9063–6.

58. Zarelli VE, Dawid IB. Inhibition of neural crest formation by Kctd15 reduces the phenotype of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis. Proc Natl Acad Sci USA. 2019;116:15116–21.

59. Zhao F, Weismann CG, Satoda M, Pierpont MEM, Sweeney E, Thompson EM, et al. Novel TFAP2B mutations that cause char syndrome provide a genotype-phenotype correlation. Am J Hum Genet. 2001;69:695–695.

60. Kusuma L, Dinesh SM, Savitha MR, Krishnamurthy B, Narayananappa D, Ramachandra NB. Mutations of TFAP2B in congenital heart disease patients in Mycow, south India. Indian J Med Res. 2011;134:621–6.

61. Ji W, Benson MA, Bhattacharya S, Chen Y, Hu L, Li F. Characterization of transcription factor AP-2 beta mutations involved in familial isolated patent ductus arteriosus suggests haploinsufficiency. J Surg Res. 2014;188:466–72.

62. Ding X, Luo C, Zhou J, Zhong Y, Hu X, Zhou F, et al. The interaction of KCTD1 with transcription factor AP-2a inhibits its transactivation. J Cell Biol. 2009;106:295–9.

63. Zarelli VE, Dawid IB. Inhibition of neural crest formation by Kctd15 involves regulation of transcription factor AP-2. Proc Natl Acad Sci USA. 2013. https://doi.org/10.1073/pnas.1300231110.

64. Liu Z, Xiang Y, Sun G. The KCTD family of proteins: Structure, function, disease relevance. Cell Biosci. 2013;3:1–5.

65. Iwamoto N, Yokoyama S. Protein kinase D regulates the adiponectin gene expression through phosphorylation of AP-2: a common pathway towards the ABCA1 gene regulation. Atherosclerosis. 2011;216:90–9.

66. Ivey KN, Sutcliffe D, Richardson J, Clyman RI, Garcia JA, Srivastava D. Mutations in TFAP2B and previously unimplicated genes of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis. Proc Natl Acad Sci USA. 2019;116:15116–21.

67. Zhao F, Weismann CG, Satoda M, Pierpont MEM, Sweeney E, Thompson EM, et al. Novel TFAP2B mutations that cause char syndrome provide a genotype-phenotype correlation. Am J Hum Genet. 2001;69:695–695.

68. Kusuma L, Dinesh SM, Savitha MR, Krishnamurthy B, Narayananappa D, Ramachandra NB. Mutations of TFAP2B in congenital heart disease patients in Mycow, south India. Indian J Med Res. 2011;134:621–6.

69. Ji W, Benson MA, Bhattacharya S, Chen Y, Hu L, Li F. Characterization of transcription factor AP-2 beta mutations involved in familial isolated patent ductus arteriosus suggests haploinsufficiency. J Surg Res. 2014;188:466–72.
with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem. 2002;277:8559–65.

75. Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren K, et al. GSA41 interacts with transcription factor AP-2β and stimulates AP-2β-mediated transactivation. Nucleic Acids Res. 2006;34:2570–8.

76. Szklarczyk D, Franceschini A, Wyder S, Forlund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015:43:D47–52.

77. Eloranta JI, Hurst HC. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumoylated in vivo. J Biol Chem. 2002;277:30798–804.

78. Gamero-Villarreal C, González LM, Rodríguez-López R, Albuquerque D, Carrillo JA, García-Herráiz A, et al. Influence of TATAFP2B and KCTD15 genetic variability on personality dimensions in anorexia and bulimia nervosa. Brain Behav. 2017;7:e00784–e00784.

79. Lesch KP, Heils A. Serotonergic gene transcriptional control regions.

80. Kim H‑S, Hong SJ, LeDoux MS, Kim K‑S. Regulation of the tyrosine hydroxylase gene promoter: constitutive and inducible activity in myometrial smooth muscle cells. Mol Pharmacol. 1999;3:67–79.

81. Williams MJ, Goergen P, Rajendran J, Klockars A, Kasagiannis A, Jong Hong S, Lardaro T, Sook OhM, Huh Y, Ding Y, Jung Kang U, et al. The genotype of human transcription factor AP-2β is associated with obesity-linked genes. J Neurochem. 2019;155:109–100.

82. Ortiz O, Delgado-García JM, Espadas I, Bahl A, Trullas R, Dreyer JL, et al. Associative learning and CA3–CA1 synaptic plasticity are impaired in D1R Null, Drd1a−/− mice and in hippocampal siRNA silenced Drd1a Mice. J Neurosci. 2010;30:12288–12288.

83. Fazio L, Pergola G, Papalino M, Carlo PD, Monda A, Gelao B, et al. Transcriptional context of DRRD1 is associated with prefrontal activity and behavior during working memory. Proc Natl Acad Sci USA. 2018;115:582–7.

84. Damberg M, Garpenstrand H, Berggård C, Åsberg M, Hallman J, Oreland L. The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophreniatr. 2015;1:14002–14002.

85. Weinschenker D. Dopamine beta-hydroxylase. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1–15.

86. Damberg M, Berggård C, Oreland L. Phelazine treatment increases transcription factor AP-2 levels in rat brain. BMC Pharmacol. 2003;3:10–10.

87. Ortiz O, Delgado-García JM, Espadas I, Bahí A, Trullas R, Dreyer JL, et al. The biological characteristics of transcription factors AP-2a and AP-2β and their importance in the regulation of DRD1. PLoS One. 2019;14(7):e0221592.

88. Hahn SL, Hahn M, Kang UJ, JoH TH. Structure of the rat aromatic l-amino acid decarboxylase gene: evidence for an alternative promoter usage. J Neurochem. 1993;60:1058–64.

89. Garlow SJ, Ciaranello RD. Transcriptional control of the rat serotonin-2 receptor gene. Mol Brain Res. 1995;35:89–100.

90. Du YL, Wilcox BD, Tettler M, Jeffrey JJ. Isolation and characterization of the rat 5-hydroxytryptamine type 2 receptor promoter: constitutive and inducible activity in myometrial smooth muscle cells. Mol Pharmacol. 1994;45:1123–31.

91. Bedford FK, Julius D, Ingraham HA. Neuronal expression of the SHT3 serotonin receptor gene requires nuclear factor 1 complexes. J Neurosci. 1998. https://doi.org/10.1523/JNEUROSCI.16-16-06189.1998.

92. Boulard S, Darmon MC, Ravassard P, Mallet J. Characterization of the transcriptional control regions of the dopamine beta-hydroxylase gene: evidence for an alternative promoter usage. J Neurochem. 1993;60:1058–64.

93. Damberg M, Berggård C, Oreland L. The influence of TFAP2B and KCTD15 polymorphisms on food intake and body weight. PLoS Genet. 2011;355:89–100.

94. Takeuchi S, Imafuku I, Waragai M, Roth C, Kanazawa I, Buettner R, et al. The biological characteristics of transcription factors AP-2a and AP-2β and their importance in the regulation of DRD1. PLoS One. 2019;14(7):e0221592.

95. Nishi A, Kurowa M, Shuto T. Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons. Front Neuroanatomy. 2011;5:43.

96. Nishi A, Kurowa M, Shuto T. Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons. Front Neuroanatomy. 2011;5:43.
in various types of cancers. 2019. Biosci Rep. https://doi.org/10.1042/ BSRO20181928.

116. Taft M, Rosen N, Twik M, BarShir R, Stein TI, Dahary D, et al. The Gen‑Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Hensch T, Wargelius HL, Herold U, Strobel A, Oreland L, Brocke B. Iłowiecka K, Glibowski P, Skrzypek M, Styk W. The long‑term dietitian Hebbar P, Abubaker JA, Abu‑Farha M, Tuomilehto J, Al‑Mulla F, Thanaraj role of central obesity‑related variants in LYPLAL1, NRXN3, and TFAP2B on quantitative metabolic traits in adult danes. PLoS ONE. 2012:7:e43212–e43212.

126. Sandholt CH, Hansen T, Pedersen O. Beyond the fourth wave of 412. Bottner A, Haidan A, Eisenhofer G, Kristensen K, Castle AL, Scherbaum biochem Biophys Res Commun. 2010;392:526–32.

130. Deibert DC, DeFronzo RA. Epinephrine‑induced insulin resistance in man. J Clin Invest. 1980;65:717–21.

139. Chernogubova E, Cannon B, Bengtsson T. Norepinephrine increases glucose transport in brown adipocytes via β 3 ‑Adrenergoreceptors through a cAMP, PKA, and β3‑Kinase‑dependent pathway stimulating conventional and novel PKCs. Endocrinology. 2004;145:269–80.

145. Mannelli M, Parenti G, Zampetti B, Canu L, Mannucci E. Diabetes from gene. J Biol Chem. 1995;270:27728–33.

150. Oreland L, Nilsson K, Damberg M, Hallman J. Monoamine oxidases—Further examination of the role of dopamine receptors in ethanol drinking, ethanol‑induced conditioned place preference, and ethanol‑induced psychomotor sensitization in mice. Psychopharmacology. 2012;222:141–53.

156. Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki T, et al. Struc‑moses. 2015;13:11. 12010.

157. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and relation to insulin sensitivity. Obes Rev. 2005;6:13–21.

158. Marette A, Bukowiecki LJ. Noradrenaline stimulates glucose transport in rat brown adipocytes by activating thermogenesis. Evidence that fatty acid activation of mitochondrial respiration enhances glucose transport. Biochemical J. 1991;277:119–24.

159. Mogi K, Yamouw M, Kondo M, Morino K, Fuke T, Obata T, Yoshizaki T, et al. Increased leptin levels in response to hypersecretion of epinephrine in pheretylalolamine‑N‑methyltransferase (PNMT)‑overexpressing mice. Endocrinology. 2000;41:4239–46.

160. Drabe M, Rüllmann M, Lüthardt J, Boettcher Y, Regenthal R, Ploetz T, et al. Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal S‑HTT availability and reward function in human obesity. Transl Psychiatry. 2017;7:e1167–e1167.

161. Zhao J, Goldberg J, Vaccarino V. Promoter methylation of serotonin transporter gene is associated with obesity measures: a monozygotic twin study. Int J Obes. 2013;37:140–5.

162. Oreland L, Hallman J, Damberg M. Platelet MAO and personality—function and dysfunction. Curr Med Chem. 2012;11:2007–16.

163. Oreland L, Nilsson K, Damberg M, Hallman J. Monoamine oxidases—activities, genotypes and the shaping of behaviour. J Neural Transm. 2007;114(6):817–22.

164. Tikkanen R, Ducci F, Goldman D, Holi M, Lindberg N, Tihonen J, et al. MAOA alters the effects of heavy drinking and childhood physical abuse on risk for severe impulsive acts of violence among alcoholic violent offenders. Alcohol Clin Exp Res. 2010. https://doi.org/10. 1111/j. 1530‑0277. 2010. 01157.x.

165. Preuss U, Wurst FM, Rüdiger M, Rüdiger M, Fehr C, Koller G, et al. Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: Results from a large multicenter association study. Drug Alcohol Depend. 2013;133:459–67.

166. Zhao R, Zhang R, Lui W, Liao Y, Tang J, Miao Q, et al. Genome‑wide DNA methylation patterns in discordant sib pairs with alcohol dependence. Asia Pac Psychiatry. 2013. https://doi.org/10.1111/appy. 12010.

167. Hodge CW, Samson HH, Chapelle AM. Alcohol self‑administration: further examination of the role of dopamine receptors in the nucleus accumbens. Alcohol Clin Exp Res. 1997;21:1083–91.

168. Bahi A, Dreyer JL. Involvement of nucleus accumbens dopamine D1 receptors in ethanol drinking, ethanol‑induced conditioned place preference, and ethanol‑induced psychomotor sensitization in mice. Psychopharmacology. 2012;222:141–53.

169. Abrahão KP, Quadros Wh, Souza‑Formigoni MLO. Nucleus accum‑bendíns dopamine D1 receptors regulate the expression of ethanol‑ induced behavioural sensitization. Int J Neuropsychopharmacol. 2011;14:175–85.
157. El-Ghundi M, George SR, Drago J, Fletcher PJ, Fan T, Nguyen T, et al. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol. 1998;353:149–58.

158. Boyce-Rustay JM, Wiedholz LM, Millstein RA, Carroll J, Murphy DL, Brookwell L, Hogan C, Healy D, Mangin D. Ninety-three cases of alcohol-seeking behavior. Eur J Pharmacol. 2006;542:149–58.

159. Bach H, Arango V, Kassir SA, Tsaava T, Dwork AJ, Mann JJ, et al. Alcoholics have more tryptophan hydroxylase 2 mRNA and protein in the dorsal and medial raphe nuclei. Alcohol Clin Exp Res. 2014. https://doi.org/10.1111/acer.12414.

160. Kuhn DM, Hasegawa H. Tryptophan hydroxylase and serotonin synthesis regulation. Handb Dev Neurosci. 2020;31:397–420.

161. SSRIs in Depression and Anxiety. SSRIs in Depression and Anxiety. 2008. https://doi.org/10.1530/ptsd.2008.028884.

162. Garcia-Miralles M, Ooi J, Ferrari-Bardile C, Tan LJJ, George M, Drum CLL, et al. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp Neurosci. 2016. https://doi.org/10.1556/23.01166.2016.

163. Bortolato M, Shih JC, et al. Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol. 2011;100:13–42.

164. Tyrer P, Srawczuk C. Monoamine oxidase inhibitors in anxiety disorders. J Psychiatric Res. 1988;22:87–98.

165. Shulman KII, Herrmann N, Walker SEE. Current place of monoamine oxidase inhibitors in depression. Curr Opin Psychiatry. 2003. https://doi.org/10.1097/00001714-200309000-00002.

166. Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry. 2012. https://doi.org/10.4088/JCP.11096su1c02.

167. Jakubovski E, Johnson JA, Nasir M, Müller-Vahl K, Bloch MH. Systematic review and meta-analysis: dose–response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019. https://doi.org/10.1002/da.22854.

168. Jans LAV, Riedel WJ, Markus CR, Böklund A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry. 2007. https://doi.org/10.1038/sj.mp.4001920.

169. Mentis A-F, Dardiotis E, Katsouni E, Chrousos GP. From warrior genes to translational solutions: novel insights into monoamine oxidases (MAOs) and aggression. Transl Psychiatry. 2021;11:130–140.

170. Kolla NJ, Vinette SA. Monoamine oxidase A in antisocial personality disorder and borderline personality disorder. Curr Behav Neurosci Rep. 2017;4:41–41.

171. Huizinga D, Haberstick BC, Smolen A, Menard S, Young SE, Corley RP, et al. Childhood maltreatment, substance use and penetrance of CYP2D6 genotype: a genomic meta-analysis in the Dunedin Multigenerational Study. Transl Psychiatry. 2017;7:110075.

172. Scott AL, Bortolato M, Chen K, Shih JC. Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. NeuroReport. 2008. https://doi.org/10.1097/WNR.0b013e328256e6c9.

173. Scott AL, Bortolato M, Chen K, Shih JC. Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. NeuroReport. 2008. https://doi.org/10.1097/WNR.0b013e328256e6c9.

174. Ramakrishnan V. MAOA gene associated with aggressive behavior in humans. J Down Syndr Chromosome Abnorm. 2017. https://doi.org/10.1016/j.jdsc.2017.11100120.

175. Cases O, Seif E, Grimsby J, Gaspar P, Chan K, Pourrinn S, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science. 1995. https://doi.org/10.1126/science.7792602.

176. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Cat-echol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA. 1998. https://doi.org/10.1073/pnas.95.17.9991.

177. Volavka J, Kennedy JL, Ni X, Czobor P, Nolan K, Sheitman B, et al. COMT158 polymorphism and hostility. Am J Med Genet Neuropsychiatric Genet. 2004. https://doi.org/10.1002/ajmg.b.20149.

178. Strous RD, Bark N, Parsia SS, Volavka J, Lachman HM. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatria. 1997. https://doi.org/10.1016/S0165-1781(96)03111-3.

179. Lee RJ, Coccaro EF. Neurotransmitters and Intermittent Explosive Disorder. In: Intermittent Explosive Disorder: Etiology, Assessment, and Treatment. Elsevier; 2019. p. 87–110.

180. Marone MD, Bourdell-Parks BN, Cameron Liles L, Weinsenker D. Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav Brain Res. 2005. https://doi.org/10.1016/j.bbr.2005.02.005.

181. Holmes A, Murphy DL, Crayleyn JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: Parallels with human anxiety and depression. Biol Psychi. 2003. https://doi.org/10.1016/j.biopsych.2003.09.003.

182. Quadros IM, Takahashi A, Miczek KA. Serotonin and aggression—an update. In: Handbook of Behavioral Neuroscience. Elsevier B.V.; 2020. p. 653–63.

183. Quadros IM, Takahashi A, Miczek KA. Serotonin and Aggression. In: Handbook of Behavioral Neuroscience. Elsevier; 2010. p. 687–713.

184. Veroude K, Zhang-James Y, Fernández-Castillo N, Bakker MJ, Cormand B, Faraone SV. Genetics of aggressive behavior: an overview. Am J Med Genet Part B Neuropsychiatric Genet. 2016. https://doi.org/10.1002/ajmb.32364.

185. Dumitrescu L, Mahoney ER, Mukherjee S, Lee ML, Bush WS, Engelmann CD, et al. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain. 2020;143:2561–75.

186. García MA, Vázquez J, Giménez C, Valdivieso F, Zafra F. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci. 1996;16:7550–6.

187. Šmeric G, Babić Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milošević N, et al. Monoaminergic neuropathology in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38.

188. Babić Leko M, Nikolac Perković M, Klepac N, Svob Strac D, Borovečki F, Pivac N, et al. Relationships of cerebrospinal fluid Alzheimer’s disease biomarkers and COMT, DBH, and MAOB single nucleotide polymorphisms. J Alzheimer’s Dis. 2020;73:135–45.

189. Pan X, Kaminga AC, Jia P, Wen SW, Acheampong K, Liu A, Carmody B, Faraone SV. Genetics of aggressive behavior: an overview. Am J Med Genet Part B Neuropsychiatric Genet. 2016. https://doi.org/10.1002/ajmb.32364.

190. Burke WJ, Chung HD, Marshall GL, Gillespie KN, Joth E. Evidence for decreases in plasma dopamine beta-hydroxylase and inflammatory cytokines in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38.

191. Mustapić M, Presečki P, Mimica N, Pivac N, Folnegović Šmalc V, Mück-Šeler D. Dopamine beta-hydroxylase and inflammatory cytokines in Alzheimer’s disease. Periodicum biologorum 112, Suppl 1 - Final Programme and Abstract Book of the 6th Croatian Congress of Pharmacology with International Participation. 2010.

192. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al. Ascend- ing monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37:1363–79.

193. Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray J, Comings DE. Phylythylamine N-methyltransferase (PNMT) gene and early-onset Alzheimer disease. J Am Geriatr Soc. 1990. https://doi.org/10.1111/j.1532-5415.1990.tb03046.x.

194. Mustapić M, Presečki P, Mimica N, Pivac N, Folnegović Smalc V, Mück-Šeler D. Dopamine beta-hydroxylase and inflammatory cytokines in Alzheimer’s disease. Prog Neurobiol. 2017;151:101–38.
199. Perkovic MN, Strac DS, Tudor L, Konjevod M, Erjavec GN, Pivac N. Catechol-O-methyltransferase, cognition and Alzheimer’s Disease. Curr Alzheimer Res. 2018;15:408–19.

200. Lukiv WJ, Rogaev EI. Genetics of aggregation in Alzheimer’s Disease (AD). Front Aging Neurosci. 2017;9:87–87.

201. Adolfsson R, Gottfries CG, Orelund L, Wiberg A, Winblad B. Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 1980;27:1029–34.

202. Patel CN, George JJ, Modi KM, Narechania MB, Patel DP, Gonzalez FJ, et al. Pharmacophore-based virtual screening of catechol-O-methyltransferase (COMT) inhibitors to combat Alzheimer’s disease. J Biomol Struct Dyn. 2018. https://doi.org/10.1080/07391102.2017.1409431.

203. Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (Review). Mol Med Rep. 2014. https://doi.org/10.3892/mmr.2014.2040.

204. Seretti A, Olgiati P. Catechol-O-Methyltransferase and Alzheimer’s Disease: A Review of Biological and Genetic Findings. CNS & Neurol Disord Drug Targets. 2012;11:299–305.

205. Smith GS, Barrett FS, Joo JH, Nassery N, Savonenko A, Sodum DJ, et al. Molecular imaging of serotonin degeneration in mild cognitive impairment. Neurobiol Dis. 2017. https://doi.org/10.1016/j.nbd.2017.05.007.

206. Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and Alzheimer’s disease. Eur Neurol. 2020;15:41–6.

207. Bradner JE, Yoo DY. HDRA. Transcriptional addiction in cancer. Cell. 2017;168:629–43.

208. Henley MJ, Koehler AN. Advances in targeting ‘undruggable’ transcription factors with small molecules. Nat Rev Drug Discov. 2021;20:669–88.

209. Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Ahsen ME, Chun Y, Grishin A, Grishina G, Stolovitzky G, Pandey G, et al. TFAP2B overexpression characterizes tumors: a study of potential tumour suppressor genes. Cell Death Dis. 2019;10:1–13.

210. Fu X, Zhang H, Chen Z, Yang Z, Shi D, Liu T, et al. TFAP2B overexpression promotes renal cell tumorigenesis by targeting TFAP2B. Oncol Lett. 2020;20:1–1.

211. Li Z, Xu X, Luo M, Hao J, Zhao S, Yu W, et al. Activator protein-2 promotes tumor growth and predicts poor prognosis in breast cancer. Cell Physiol Biochem. 2018;47:1925–35.

212. Pellikainen JM, Kosma V-M. Activator protein-2: role in carcinogenesis with a special reference to breast cancer—a mini review. Int J Cancer. 2007;120:2061–7.

213. Raap M, Gromov M, Christgen H, Glage S, Bentes-Alj M, Koren S, et al. Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2B. Mol Carcinog. 2017;56:1909–23.

214. Beger M, Butz K, Denk C, Williams T, Hurst HC, Hoppe-Seyler JS. Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription. J Mol Med. 2001;79:314–20.

215. Bence M, Koller J, Sasvári-Szekely M, Keszler G. Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells. J Neural Transm. 2012;119:17–24.

216. Fontaine T, Overman J, François M. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell Regen. 2019. https://doi.org/10.1186/s13619-015-0015-x.

217. Yan C, Higgins P. Drugging the undruggable Transcription therapy for cancer. Biochem Biophys Acta. 2013;1835:76–85.

218. Mohamad Anuar NN, Nor Hisam NLS, Liew SL, Ugusman A. Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent. Front Pharmacol. 2020;11:1817–1817.

219. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Ayer RA, Maywald RL, Buford AS, et al. An oral formulation of YK-4-279: Preclinical efficacy and acquired resistance patterns in Ewing sarcoma. Mol Cancer Ther. 2015. https://doi.org/10.1158/1158-7163.MCT-14-0334.

220. Lambert M, Jambon S, Depauw S, David-Cordonnier MH. Targeting transcription factors for cancer treatment. Molecules. 2018;23:1479.

221. Bushwellner JH. Targeting transcription factors in cancer — from undruggable to reality. Nat Rev Cancer. 2019. https://doi.org/10.1038/s41568-019-0196-7.

222. Inamoto I, Shin JA. Peptide therapeutics that directly target transcription factors. Pept Sci. 2019;111:e24048–e24048.

223. Ozer M, Warren CB, Ansari AZ. Determining DNA sequence specificity of natural and artificial transcription factors by cognate site identifier analysis. Methods Mol Biol. 2009;544:637–53.

224. Allen-Petersen BL, Sears RC. Mission possible: advances in MYC therapeutic targeting in cancer. BioDrugs. 2019. https://doi.org/10.1007/s41556-019-00370-5.

225. Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RF, Davis LE, et al. TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results. JCO. 2021;39:11500–11500.

226. Robledinos-Antòn N, Fernández-Cañés R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev. 2019. https://doi.org/10.1155/2019/9372182.

227. Ghosh D, Papavassiliou AG. Transcription factor therapeutics: long-shot or lodestone? Curr Med Chem. 2005;12:691–701.

228. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Branca MA. Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol. 2019;37:29–37.

229. Frantz S. Playing dirty. Nature. 2005;437:942–3.

230. Rothstein M, Simões-Costa M. Heterodimerization of TFAP2 pioneer factors drives epigenetic targeting in cancer. BioDrugs. 2019. https://doi.org/10.1007/s41556-019-00370-5.

231. Wu H, Zhang J. Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data. Gynecol Oncol. 2018;149:592–7.

232. Oya M, Mikami S, Mizuno R, Miyajima A, Horiguchi Y, Nakashima J, et al. Differential expression of activator protein-2 isoforms in renal cell carcinoma. Urology. 2004;64:162–7.

233. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE. 2010;5:e10696.

234. Zhu M, Zou L, Lu F, Ye L, Su B, Yang K, et al. miR-142-5p promotes renal cell tumorigenesis by targeting TFAP2B. Oncol Lett. 2020;20:1–6.

235. Liu J, Xu X, Luo M, Hao J, Zhao S, Yu W, et al. Activator protein-2B promotes tumor growth and predicts poor prognosis in breast cancer. Cell Physiol Biochem. 2018;47:1925–35.
246. Davies SR, Sakano S, Zhu Y, Sandell LJ. Distribution of the transcription factors Sox9, AP-2, and [delta]EF1 in adult murine articular and meniscal cartilage and growth plate. J Histochim Cytochem. 2002;50:1059–65.

247. Seberg HE, Van Otterloo E, Loftus SK, Liu H, Bonde G, Sompallae R, et al. TPAP2 paralog regulates melanocyte differentiation in parallel with MITF. PLoS Genet. 2017;13:e1006636–e1006636.

248. Chambers BE, Gerlach GF, Clark EG, Chen KH, Levesque AE, Leshchiner K, et al. TFAP2a is a novel gatekeeper of nephron differentiation during kidney development. Development. 2019;146:dev172387.

249. Kuckenberg F, Kulaizcza C, Schorle H. The role of transcription factor Tcfap2c/TFAP2C in trophoderm development. Reprod Biomed Online. 2012;25:12–20.

250. Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT, et al. TFAP2A mutations result in Brachio-Oculo-facial syndrome. The Am J Hum Genet. 2008;82:1171–7.

251. Huang HY, Yang Y, Yan J, Tang XY, Pan Q. TFAP2A is a novel regulator that modulates ferroptosis in gallbladder carcinoma cells via the Nrf2 signaling axis. Eur Rev Med Pharmacol Sci. 2020;24:4745–55.

252. Li Q, Dashwood RH. Activator Protein 2α associates with adenosomatous polyposis Coli/β-catenin and inhibits β-Catenin/cell factor transcriptional activity in colorectal cancer cells. J Biol Chem. 2004;279:45669–45669.

253. Makhov PB, Golovine KV, Kutikov A, Canosa M, Berlato C, Mutschler WC, et al. Reversal of epigenetic silencing of AP-2α results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells. Carcinogenesis. 2011;32:1773–81.

254. Hallberg AR, Vornink SU, Hudakchek DR, Cramer-Morales K, Milhem MM, Cornell RA, et al. Aberrant Cpg methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma. Epigenetics. 2014;9:1641–7.

255. Lian W, Zhang L, Yang L, Chen W. AP-2α reverses vincristine-induced multidrug resistance of SGC7901 gastric cancer cells by inhibiting the Notch pathway. Apoptosis. 2017;22:933–41.

256. Su W, Xia J, Chen X, Xu M, Nie L, Chen N, et al. Ectopic expression of AP-2α transcription factor suppresses glioma progression. Int J Clin Exp Pathol. 2014;7:8666–8666.

257. Sotiriou C, Miroux V, Lorusso F, Loi S, Ellis OA, et al. Expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–72.

258. Shi D, Xie F, Zhang Y, Tian Y, Chen W, Fu L, et al. TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1α signaling pathway. Cancer Prev Res (Phila). 2011;4:7386–7.

259. Bennett KL, Romigh T, Eng C. AP-2alpha induces epigenetic silencing of tumor suppressive genes and microsatellite instability in head and neck squamous cell carcinoma. PLoS ONE. 2009;4:e6931.

260. Ding X, Yang Z, Zhou F, Wang F, Li X, Chen C, et al. Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression. J Biol Chem. 2011;286:17741–7.

261. Camière C, Moritz H, Posada G, Bresolin M, Grespan JJ, Koc J, et al. Ectopic expression of AP-2α splice variants in pancreatic cancer: Pancreas. 2011;40:695–700.

262. Schulte JH, Kirfel J, Lim S, Schramm A, Friedrichs N, Deubzer HE, et al. Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. Cancer Lett. 2009;275:345–50.

263. Yang Y-L, Zhao L-Y. AP-2 family of transcription factors: critical regulators of vomeronasal organ development. Mol Neurobiol. 2012;46:15–28.

264. Ebert MPA, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. Science. 2020;369:1176–82.

265. Kaiser S, Koch Y, Kuhn S, Sharma N, Gellhaus A, Kuckenberg P, et al. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma. Epigenetics. 2014;9:1641–7.

266. Yang Y, Liao Y, Zhao L-Y, AP-2 family of transcription factors: critical regulators of human development and cancer. J Cancer Treat Diagn. 2021;5:1–4.

267. Ebert MPA, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. Cancer Prev Res (Phila). 2014;7:266–72.

268. Lal G, Contreras PG, Kulak M, Woodfield G, Bair T, Domann FE, et al. Human Melanoma cells over-express extracellular matrix 1 (ECM1) which is regulated by TFAP2C. PLoS ONE. 2013;8:e73953.

269. Williams CM, Sicbetta AG, Friedrich JK, Canosa M, Berlato C, Mutschler WC, et al. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J. 2009;28:3591–601.

270. Cheng C, Yang Y, Xu M, Zhao W, Zhou H, Huang Y, et al. Cloning and characterization of a novel human transcription factor AP-2 beta like gene (TFAP2BL1). Int J Biochem Cell Biol. 2002;34:78–86.

271. Zhao F, Luftin T, Gelb BD. Expression of Tafap2d, the gene encoding the transcription factor Ap-2 delta, during mouse embryogenesis. Gene Expr Patterns. 2003;3:213–7.

272. Jain S, Gluebrecht DD, Germain DR, Moser M, Goodboum R. AP-2 expression in developing retina: contributing to the molecular diversity of amacrine cells. Sci Rep. 2018;8:1–13.

273. Sun L, Zhao Y, Gu S, Mao Y, Ji C, Xin X. Regulation of the HMOX1 gene by the transcription factor AP-2β with unique DNA binding site. Mol Med Rep. 2014;10:423–8.

274. Fraune C, Harms L, Buschek F, Hofmayer D, Tsoirulakis MC, Clauditz TS, et al. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Mol Med. 2020;26:1–13.

275. Wenke AK, Bossheroff AK. Roles of AP-2 transcription factors in the regulation of cartilage and skeletal development. FEBS J. 2010;277:894–902.

276. Lin JM, Taroc EJM, Frais JA, Prasad A, Catzone AN, Sammons MA, et al. The transcription factor Tafap2e/PAF-2e plays a pivotal role in maintaining the identity of basal vomeronasal sensory neurons. Dev Biol. 2018;441:67–82.

277. Enomoto T, Iwamoto M, Iwata T, Uno A, Saitou M, Yamaguchi T, et al. Development/Plasticity/Repair Bcl11b/Ctip2 controls the differentiation of vomeronasal sensory neurons in mice. J Neurosci. 2011. https://doi.org/10.1523/JNEUROSCI.1245-11.2011.

278. Wenke AK, Grässel S, Moser M, Bossheroff AK. The cartilaginous-specific transcription factor Sox9 regulates AP-2α expression in chondrocytes. FEBS J. 2009;276:2494–504.

279. Feng W, Simeons-de-Souza F, Finger TE, Restrepo D, Williams T. Disorganized olfactory bulb lamination in mice deficient for transcription factor Ap-2(eopen). Mol Cell Neurosci. 2009;42:161–71.

280. Niebler S, Bossheroff AK. The transcription factor activating enhancer-binding protein epsilon (AP-2ε) regulates the core promoter of type II collagen (COL2A1). FEBS J. 2013;280:1397–408.

281. Wenke AK, Rothhammer T, Moser M, Bossheroff AK. Regulation of integrin alpha10 expression in chondrocytes by the transcription factors AP2epsilon and Ets-1. Biochem Biophys Res Commun. 2006;345:495–501.

282. Ebert MPA, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med. 2012;366:44–53.

283. Hoshi R, Watanabe Y, Ishizuka Y, Hirano T, Nagasaki-Maeoka E, Yoshizawa S, et al. Depletion of TFAP2E attenuates adriamycin-mediated apoptosis in human neuroblastoma cells. Oncol Rep. 2017;37:2459–64.